OSI Pharmaceuticals Overview
- Founded
-
1983
- Status
-
Acquired/Merged
- Employees
-
557
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
4
OSI Pharmaceuticals General Information
Description
Manufacturer and seller of cancer medicines. The company engages in discovering, developing and commercialization of molecular targeted therapies used in oncology, diabetes and obesity disease. It also manufactures and sells cancer medicine Tarceva.
Contact Information
Website
www.prosidion.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- 41 Pinelawn Road
- Melville, NY 11747
- United States
OSI Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OSI Pharmaceuticals Patents
OSI Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170273982-A1 | Pulse dosing regimen and methods of treatment | Granted | 25-Mar-2016 | 000000000 | |
| US-20220133725-A1 | Pulse dosing regimen and methods of treatment | Pending | 25-Mar-2016 | 0000000000 | |
| US-10583142-B2 | Pulse dosing regimen and methods of treatment | Active | 25-Mar-2016 | 000000000 | |
| US-11253520-B2 | Pulse dosing regimen and methods of treatment | Active | 25-Mar-2016 | 000000000 | |
| US-20200230142-A1 | Pulse dosing regimen and methods of treatment | Granted | 25-Mar-2016 | A61K31/517 |
OSI Pharmaceuticals Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Neil Gibson Ph.D | Chief Scientific Officer |
OSI Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OSI Pharmaceuticals Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000 | 25-Jun-2009 | 00000 0000 | 0000 | Biotechnology | |
| 0000000 00000 | 14-Nov-2005 | 0000000000 | 00000 | Pharmaceuticals | |
| 0000 00000000 | 12-Jun-2003 | 0000000000 | 0000 | Biotechnology | |
| Gilead Sciences (Oncology Assets) | 26-Nov-2001 | Corporate Asset Purchase | 00000 | Buildings and Property | 00000 000 |
OSI Pharmaceuticals Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 00000000 | 25-Jun-2009 | 00000 00000 00 | 0000 | Completed |
|
| Eyetech Pharmaceuticals | 14-Nov-2005 | Merger/Acquisition | 00000 | Completed |